Literature DB >> 29656495

Randomized controlled clinical study assessing two membranes for guided bone regeneration of peri-implant bone defects: 3-year results.

Tobias Basler1, Nadja Naenni1, David Schneider1, Christoph H F Hämmerle1, Ronald E Jung1, Daniel S Thoma1.   

Abstract

OBJECTIVES: To assess two- and three-dimensional changes of the peri-implant tissues as well as clinical, biological, and radiological outcomes of implants having been treated with resorbable or nonresorbable membranes at 3 years.
MATERIALS AND METHODS: Twenty-three patients were re-examined after having received a single-tooth implant in the esthetic zone in conjunction with guided bone regeneration (GBR) using either a resorbable (RES) or a titanium-reinforced nonresorbable membrane (N-RES) and demineralized bovine bone mineral. Volumetric and linear as well as clinical and radiographic measurements were performed at crown insertion (baseline), at 1 year (FU-1) and 3 years (FU-3). Statistics were performed by means of parametric and nonparametric tests.
RESULTS: Minor, but ongoing buccal volume loss was observed in both groups during the 3-year follow-up. A slightly higher volume loss was observed in group RES (-0.22 mm) compared to N-RES (-0.14 mm) at 1 year (FU-1), but aligned at 3 years (FU-3) RES (-0.30 mm) N-RES (-0.32 mm). All changes over time were statistically significantly different within (p < .05), but not between the groups (p > .05). Stable median interproximal bone levels after 3 years (FU-3); 0.26 mm (0.04; 0.36) (RES) and 0.14 mm (0.08; 0.20) (N-RES) and healthy tissues (BOP, PD) were obtained with both membranes.
CONCLUSIONS: Both treatment modalities resulted in minor, but ongoing contour changes of the peri-implant tissues. Stable interproximal bone levels and healthy tissues can be obtained with membranes up to 3 years.
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  alveolar ridge augmentation; dental implants; membranes; volume stability; volumetric analysis

Mesh:

Substances:

Year:  2018        PMID: 29656495     DOI: 10.1111/clr.13147

Source DB:  PubMed          Journal:  Clin Oral Implants Res        ISSN: 0905-7161            Impact factor:   5.977


  6 in total

1.  Primary bone augmentation leads to equally stable marginal tissue conditions comparing the use of xenograft blocks infused with BMP-2 and autogenous bone blocks: A 3D analysis after 3 years.

Authors:  Stefan P Bienz; Michael Payer; Jenni Hjerppe; Jürg Hüsler; Norbert Jakse; Patrick R Schmidlin; Christoph H F Hämmerle; Ronald E Jung; Daniel S Thoma
Journal:  Clin Oral Implants Res       Date:  2021-09-28       Impact factor: 5.021

2.  Guided bone regeneration simultaneous with implant placement using bovine-derived xenograft with and without liquid platelet-rich fibrin: a randomized controlled clinical trial.

Authors:  Gözde Işık; Meltem Özden Yüce; Nazan Koçak-Topbaş; Tayfun Günbay
Journal:  Clin Oral Investig       Date:  2021-05-28       Impact factor: 3.573

3.  Degradation, Bone Regeneration and Tissue Response of an Innovative Volume Stable Magnesium-Supported GBR/GTR Barrier Membrane.

Authors:  Mike Barbeck; Lennart Kühnel; Frank Witte; Jens Pissarek; Clarissa Precht; Xin Xiong; Rumen Krastev; Nils Wegner; Frank Walther; Ole Jung
Journal:  Int J Mol Sci       Date:  2020-04-28       Impact factor: 5.923

4.  Contour changes of peri-implant tissues are minimal and similar for a one- and a two-piece implant system over 12 years.

Authors:  Miha Pirc; Oliver Harbeck; Vitor M Sapata; Jürg Hüsler; Ronald E Jung; Christoph H F Hämmerle; Daniel S Thoma
Journal:  Clin Oral Investig       Date:  2020-10-15       Impact factor: 3.573

5.  Clinical Efficacy and Safety of Different Dental Prosthetic Membranes in Guided Bone Regeneration during Dental Implants: A Meta-Analysis.

Authors:  Yan Guo; Linghan Su; Caidi Chen; Yan Liu; Jianxue Li
Journal:  Comput Intell Neurosci       Date:  2022-07-31

6.  Puerarin improves graft bone defect through microRNA‑155‑3p‑mediated p53/TNF‑α/STAT1 signaling pathway.

Authors:  Yang Zhou; Hongyu Lian; Kexin Liu; Deli Wang; Xuelian Xiu; Zhang Sun
Journal:  Int J Mol Med       Date:  2020-05-06       Impact factor: 4.101

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.